Evaluate Pharma, the premier destination for consensus forecasts trusted by pharmaceutical firms, investment banks, and consultancies alike.
Assess your portfolio’s performance, combining financial, clinical, and regulatory data to determine the true value of your assets
Leverage data to evaluate clinical trial progress, market potential, and competitive landscapes, ensuring you focus on high-value opportunities.
Forecast asset value and guide your investment strategy, factoring in market conditions, clinical outcomes, and regulatory developments.
Screening and valuing pharma assets is a complex business and making sense of all the data points can be a real challenge. Our solutions provide an accurate, impartial, and timely view of pharma asset potential. Forecast product-level risk, costs, and timelines to make key commercial decisions with confidence.
Check your assumptions, conduct deep due diligence, and assess the value of a potential target or your own portfolio with objectivity. Whether you are looking to expand your product pipelines or enter new markets, find out how our asset screening tools can inform your strategic decision-making.
Tracking potential partners and acquisition targets helps you seize opportunities and manage portfolio risk. But company profiling can be complex and time-consuming. As your team sifts through multiple datasets, how do you find timely insights and avoid bias?
Our solutions enable you to find and track the right companies to strengthen your growth strategy. Easily track financials, pipeline developments, M&A activity, and more. Validate potential investments with confidence and strategically prioritize your portfolio for the highest return.
Our experts can help you turn this use case into actionable strategy
Our consulting and analytics teams work alongside you to solve complex commercial and strategic challenges. Combining Evaluate’s trusted data with Norstella’s global expertise, we deliver tailored insights that help you make smarter, faster, and more confident business decisions.
Explore related products that help you deepen your understanding and move forward with confidence.
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Mark leads client engagements focused on asset strategy, portfolio prioritization, opportunity assessment, forecasting and valuation, and development strategy across pharma and biotech portfolios. Mark brings over 25 years of biopharma and life sciences experience, having worked across academia, large pharma, and consulting roles. His background includes hands-on experience as a medicinal chemist, followed by senior analytical and advisory positions supporting strategic decision-making in R&D and commercial planning.
Paul leads the Evaluate’s consulting and analytics business, overseeing strategic advisory engagements across portfolio strategy, asset strategy, competitive intelligence, forecasting, valuation, and BD&L, working with clients across the global pharma and biotech ecosystem.
Paul brings extensive experience spanning academic research and life sciences consulting, supporting organizations ranging from early-stage biotech companies to large pharmaceutical corporate strategy teams. His work focuses on helping clients make evidence-based decisions across the product lifecycle, from pipeline prioritization through to commercial strategy and investment decision-making.
Ben specializes in quantitative analysis, leading projects covering buy and sell side due diligence, deal benchmarking, pipeline tracking, competitor analysis and product forecasting across a broad range of indications and markets, with an increasing focus on rare diseases. Recent work has included building prioritization models that can be used to identify in-licensing opportunities, out licensing partners, attractive indications, or technologies. Ben has authored multiple peer-reviewed journal articles and industry standard guideline documents.
As a neuroscientist, consultant and commercial leader, Kelly brings more than 16 years of experience in the life sciences sector. She partners with insights, analytics, and commercial strategy teams to transform how pharmaceutical organizations capture and operationalize market intelligence. At Evaluate, Kelly focuses on creative solutioning, bringing together life science consultants, data scientists, and subject‑matter experts to build custom intelligence programs and products that leverage the full breadth of Norstella’s assets, including gold-standard forecasting, real‑world data, market access insights, and expert journalistic intelligence. With expertise in competitive landscape analysis, tech-enabled secondary monitoring, primary research, and comprehensive conference coverage, her work supports translation of complex market signals into clear, actionable insights. Kelly holds a PhD in Neuroscience from Georgetown University and completed a postdoctoral fellowship at the National Institute of Neurological Disorders and Stroke (NINDS).
Markella brings 20 years of industry and consulting experience, with deep knowledge and expertise in oncology, rare disease and ophthalmology. She specializes in CI landscaping projects in specialty indications and has led our largest CI monitoring projects since 2020. She has led Norstella’s largest conference coverage engagements with Top 10 Pharma clients and brings on-the-ground, secondary and primary CI expertise. She holds an MBA from Baruch College and a master’s in biotechnology from Columbia University.
Get in touch with our team to explore the right solutions for your business.
